Brokers Offer Predictions for Immunovant, Inc.’s FY2026 Earnings (NASDAQ:IMVT)

Immunovant, Inc. (NASDAQ:IMVT) – Research analysts at Leerink Partnrs decreased their FY2026 earnings estimates for shares of Immunovant in a research report issued on Monday, September 9th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($2.82) per share for the year, down from their previous forecast of ($2.72). The consensus estimate for Immunovant’s current full-year earnings is ($2.43) per share. Leerink Partnrs also issued estimates for Immunovant’s FY2027 earnings at ($2.99) EPS, FY2028 earnings at ($2.52) EPS and FY2029 earnings at ($1.38) EPS.

Several other research firms also recently commented on IMVT. Oppenheimer decreased their price target on shares of Immunovant from $50.00 to $46.00 and set an “outperform” rating on the stock in a research note on Monday, June 3rd. JPMorgan Chase & Co. decreased their target price on shares of Immunovant from $51.00 to $46.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. UBS Group dropped their price target on shares of Immunovant from $42.00 to $41.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunovant in a research note on Monday, September 9th. Finally, HC Wainwright restated a “buy” rating and set a $51.00 price objective on shares of Immunovant in a research note on Tuesday. Fifteen investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $48.40.

Immunovant Price Performance

Shares of NASDAQ IMVT opened at $29.67 on Thursday. The firm has a market cap of $4.34 billion, a price-to-earnings ratio of -15.62 and a beta of 0.67. The stock’s fifty day moving average price is $29.89 and its two-hundred day moving average price is $29.60. Immunovant has a one year low of $19.50 and a one year high of $45.58.

Immunovant (NASDAQ:IMVT) last announced its earnings results on Tuesday, August 6th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.07). During the same period in the prior year, the company posted ($0.57) earnings per share.

Insiders Place Their Bets

In related news, CTO Jay S. Stout sold 2,813 shares of the stock in a transaction that occurred on Wednesday, July 24th. The shares were sold at an average price of $27.76, for a total value of $78,088.88. Following the completion of the transaction, the chief technology officer now owns 144,926 shares of the company’s stock, valued at approximately $4,023,145.76. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CTO Jay S. Stout sold 2,813 shares of the business’s stock in a transaction on Wednesday, July 24th. The stock was sold at an average price of $27.76, for a total transaction of $78,088.88. Following the sale, the chief technology officer now owns 144,926 shares in the company, valued at approximately $4,023,145.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Michael Geffner sold 3,456 shares of the stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $27.76, for a total value of $95,938.56. Following the completion of the transaction, the insider now owns 138,160 shares of the company’s stock, valued at $3,835,321.60. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 31,475 shares of company stock valued at $904,638. 5.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Immunovant

Large investors have recently modified their holdings of the business. Assetmark Inc. acquired a new stake in Immunovant in the fourth quarter valued at $61,000. Quest Partners LLC raised its position in shares of Immunovant by 216.7% during the second quarter. Quest Partners LLC now owns 2,610 shares of the company’s stock worth $69,000 after acquiring an additional 1,786 shares during the last quarter. Headlands Technologies LLC acquired a new position in shares of Immunovant in the second quarter worth approximately $77,000. EntryPoint Capital LLC boosted its holdings in Immunovant by 288.8% in the first quarter. EntryPoint Capital LLC now owns 2,912 shares of the company’s stock valued at $94,000 after acquiring an additional 2,163 shares during the last quarter. Finally, DNB Asset Management AS increased its position in Immunovant by 10.3% during the 2nd quarter. DNB Asset Management AS now owns 10,290 shares of the company’s stock valued at $271,000 after purchasing an additional 958 shares during the period. Institutional investors own 47.08% of the company’s stock.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.